Bank of Nova Scotia
AERI

Bank of Nova Scotia’s Aerie Pharmaceuticals AERI Stock Holding History

Bank of Nova Scotia’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-22,200
Closed -$1.33M – 1026
2017
Q4 		$1.33M Sell
22,200
-100
-0.4% -$6.06K 0.01% 707
2017
Q3 		$1.08M Hold
22,300
– – 0.01% 719
2017
Q2 		$1.17M Sell
22,300
-39,100
-64% -$1.82M 0.01% 727
2017
Q1 		$2.79M Buy
+61,400
New +$2.74M 0.01% 540

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of Nova Scotia's AERI Position: Q1 2018 in Review

Bank of Nova Scotia sold out of Aerie Pharmaceuticals (AERI) in Q1 2018, closing a stake of 22,200 shares — an estimated $1.33M sold.

Bank of Nova Scotia first reported a position in AERI in Q1 2017 and held it in 4 quarters. The position peaked at $2.79M in Q1 2017. 172 funds tracked by Wall St. Rank hold AERI as of Q1 2018.

  • Bank of Nova Scotia reported no remaining Aerie Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Bank of Nova Scotia sold 22,200 Aerie Pharmaceuticals shares in Q1 2018, an estimated $1.33M.
  • Bank of Nova Scotia first reported a position in Aerie Pharmaceuticals in Q1 2017 and held it in 4 quarters.
  • Bank of Nova Scotia's Aerie Pharmaceuticals position peaked at $2.79M in Q1 2017.
  • 172 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2018.

Based on Bank of Nova Scotia's 13F filing for Q1 2018, filed 15 May 2018.